A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

NCT05126719 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

238

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: MRG003
DRUG: Capecitabine tablets
DRUG: Docetaxel injection

Sponsor

Shanghai Miracogen Inc.